Search results for "PEROXISOME"

showing 10 items of 232 documents

Progressive Endoplasmic Reticulum Stress Contributes to Hepatocarcinogenesis in Fatty Acyl-CoA Oxidase 1–Deficient Mice

2011

Fatty acyl-coenzyme A oxidase 1 (ACOX1) knockout (ACOX1(-/-)) mice manifest hepatic metabolic derangements that lead to the development of steatohepatitis, hepatocellular regeneration, spontaneous peroxisome proliferation, and hepatocellular carcinomas. Deficiency of ACOX1 results in unmetabolized substrates of this enzyme that function as biological ligands for peroxisome proliferator-activated receptor-α (PPARα) in liver. Here we demonstrate that sustained activation of PPARα in ACOX1(-/-) mouse liver by these ACOX1 substrates results in endoplasmic reticulum (ER) stress. Overexpression of transcriptional regulator p8 and its ER stress-related effectors such as the pseudokinase tribbles h…

medicine.medical_specialtyGenotypePeroxisome proliferator-activated receptorPeroxisome ProliferationMice TransgenicBiologyEndoplasmic ReticulumModels BiologicalPathology and Forensic MedicineMiceInternal medicinemedicineAnimalsHumansAcyl-CoA oxidasePPAR alphaTransgenesDNA Primerschemistry.chemical_classificationLiver cellEndoplasmic reticulumLiver NeoplasmsRegular ArticlePeroxisomemedicine.diseaseNeoplasm ProteinsCell biologyDNA-Binding ProteinsMice Inbred C57BLEndocrinologyGene Expression RegulationLiverchemistryHepatocytesUnfolded protein responseAcyl-CoA OxidaseSteatohepatitisThe American Journal of Pathology
researchProduct

Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.

2004

Type 2 diabetes is an important cardiovascular risk factor. A significant component of the risk associated with type 2 diabetes is thought to be because of its characteristic lipid "triad" profile of raised small dense low-density lipoprotein levels, lowered high-density lipoprotein, and elevated triglycerides (TGs). Trials of statins and fibrates have included substantial numbers of patients with diabetes and indicate that lipid lowering reduces cardiovascular event rates in these patients. However, statins alone do not always address all the lipid abnormalities of diabetes. Fibrates, which have low affinity for peroxisome proliferator-activated receptor alpha (PPARalpha), improve most asp…

medicine.medical_specialtyLipoproteinsPeroxisome proliferator-activated receptorType 2 diabetesInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineLipolysisHumansPPAR alphaDyslipidemiaschemistry.chemical_classificationbusiness.industrynutritional and metabolic diseasesLipid metabolismmedicine.diseaseLipid MetabolismEndocrinologychemistryDiabetes Mellitus Type 2Cardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaLipoproteinAmerican heart journal
researchProduct

PGC-1α: a master gene that is hard to master

2012

Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a transcriptional coactivator that favorably affects mitochondrial function. This concept is supported by an increasing amount of data including studies in PGC-1α gene-deleted mice, suggesting that PGC-1α is a rescue factor capable of boosting cell metabolism and promoting cell survival. However, this view has now been called into question by a recent study showing that adeno-associated virus-mediated PGC-1α overexpression causes overt cell degeneration in dopaminergic neurons. How is this to be understood, and can these seemingly conflicting findings tell us something about the role of PGC-1α in cell stress and in cont…

medicine.medical_specialtyModels NeurologicalSettore BIO/11 - Biologia MolecolareRNA-binding proteinBiologyMitochondrionSettore BIO/09 - FisiologiaMiceCellular and Molecular NeuroscienceHeat shock proteinInternal medicinemedicineAnimalsHomeostasisHumansReceptorMolecular BiologyTranscription factorHeat-Shock ProteinsMice KnockoutPharmacologyPGC-1α Mitochondria Dopaminergic neurons Transgenic animal Adenovirus Parkinson’s diseaseDopaminergic NeuronsDopaminergicRNA-Binding ProteinsParkinson DiseaseCell BiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaEndocrinologyCell metabolismNerve DegenerationTrans-ActivatorsMolecular MedicineNeuroscienceHomeostasisTranscription FactorsCellular and Molecular Life Sciences
researchProduct

The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice

2009

Oleoylethanolamide (OEA) is an endogenous lipid produced in the intestine that mediates satiety by activation of peroxisome proliferator-activated receptor alpha (PPARalpha). OEA inhibits gastric emptying and intestinal motility, but the mechanism of action remains to be determined. We investigated whether OEA inhibits intestinal motility by activation of PPARalpha. PPARalpha immunoreactivity was examined in whole mount preparations of mouse gastrointestinal (GI) tract. The effect of OEA on motility was assessed in wildtype, PPARalpha, cannabinoid CB(1) receptor and CB(2) receptor gene-deficient mice and in a model of accelerated GI transit. In addition, the effect of OEA on motility was as…

medicine.medical_specialtyPhysiologymedicine.medical_treatmentTRPV Cation ChannelsMotilityOleic AcidsBiologydigestive systemReceptor Cannabinoid CB2MiceOleoylethanolamidechemistry.chemical_compoundReceptor Cannabinoid CB1Glucagon-Like Peptide 1Internal medicinemedicineAnimalsPPAR alphaReceptorMice KnockoutGastric emptyingEndocrine and Autonomic Systemsdigestive oral and skin physiologyGastroenterologyImmunohistochemistryEndocannabinoid systemEndocrinologyMechanism of actionchemistrylipids (amino acids peptides and proteins)CannabinoidPeroxisome proliferator-activated receptor alphamedicine.symptomGastrointestinal MotilityEndocannabinoids
researchProduct

Effects of high-fat diet and physical activity on pyruvate dehydrogenase kinase-4 in mouse skeletal muscle

2012

Abstract Background The expression of PDK4 is elevated by diabetes, fasting and other conditions associated with the switch from the utilization of glucose to fatty acids as an energy source. It is previously shown that peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a master regulator of energy metabolism, coactivates in cell lines pyruvate dehydrogenase kinase-4 (PDK4) gene expression via the estrogen-related receptor α (ERRα). We investigated the effects of long-term high-fat diet and physical activity on the expression of PDK4, PGC-1α and ERRα and the amount and function of mitochondria in skeletal muscle. Methods Insulin resistance was induced by a high-fat (HF) d…

medicine.medical_specialtyPyruvate dehydrogenase kinaseEndocrinology Diabetes and MetabolismPDK4Skeletal muscleMedicine (miscellaneous)lcsh:TX341-641Pyruvate dehydrogenase phosphataseBiologyInternal medicineCoactivatormedicinelcsh:RC620-627Nutrition and DieteticsResearchSkeletal muscleFuel switchingPeroxisomePyruvate dehydrogenase complexLipidsMitochondrialcsh:Nutritional diseases. Deficiency diseasesEndocrinologymedicine.anatomical_structureGlucoseBiochemistryEnergy sourcelcsh:Nutrition. Foods and food supplyNutrition & Metabolism
researchProduct

PPAR alpha gene variants as predicted performance-enhancing polymorphisms in professional Italian soccer players

2014

Patrizia Proia,1 Antonino Bianco,1 Gabriella Schiera,2 Patrizia Saladino,2 Valentina Contrò,1 Giovanni Caramazza,3 Marcello Traina,1 Keith A Grimaldi,4 Antonio Palma,1 Antonio Paoli5 1Sport and Exercise Sciences Research Unit, 2Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy; 3Regional Sports School of CONI Sicilia, Sicily, Italy; 4Biomedical Engineering Laboratory, Institute of Communication and Computer Systems, National Technical University of Athens, Athens, Greece; 5Department of Biomedical Sciences, University of Padova, Padua, Italy Background: The PPARα gene encodes the peroxisome proliferato…

medicine.medical_specialtyTaqIperoxisome proliferator-activator receptor alpha endurance athletesG allelegene variantsPCR-RFLPchemistry.chemical_compoundBlood serumPolymorphism (computer science)Endurance trainingInternal medicineSettore BIO/10 - BiochimicaGenotypemedicineAlleleOpen Access Journal of Sports MedicineOriginal Researchmedicine.diagnostic_testbusiness.industryEndocrinologychemistryendurance athleteRestriction fragment length polymorphismbusinessLipid profilehuman activities
researchProduct

Combined sub-optimal doses of Rosuvastatin and Bexarotene impairs angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox…

2015

Aim: Mononuclear cell (MC) infiltration into the arterial subendothelium is a key event in atherogenesis. Rosuvastatin (Rosu) and bexarotene (Bex) exert anti-inflammatory activity, but serious dose-related adverse effects have emerged. The need for safer and effective strategies to prevent and treat atherosclerosis led us to test the effect of combined use of both drugs on angiotensin II (Ang-II)-induced arterial MC recruitment. Results: Vehicle, Rosu (10–30 nM), Bex (0.3–1 μM), or a combination of both were administered to human umbilical arterial endothelial cells (HUAECs) 20 h before stimulation with 1 μM Ang-II (4 h). Surprisingly, a combination of Rosu (10 nM)+Bex (0.3 μM), which did n…

medicine.medical_specialtyTetrahydronaphthalenesPhysiologyPeroxisome Proliferator-Activated ReceptorsClinical BiochemistryCCL2BiologyNitric OxideBiochemistryPeripheral blood mononuclear cellCell LineInternal medicineCell AdhesionmedicineAnticarcinogenic AgentsHumansRosuvastatinInterleukin 8Rosuvastatin CalciumMolecular BiologyGeneral Environmental ScienceSistema cardiovascularBexaroteneSulfonamidesDiabetisArtèriesAngiotensin IIMembrane ProteinsNADPH OxidasesArteriesCell BiologyAngiotensin IIFluorobenzenesCXCL1Original Research CommunicationsPyrimidinesRetinoid X ReceptorsEndocrinologyNADPH Oxidase 5BexaroteneLeukocytes MononuclearGeneral Earth and Planetary SciencesSignal transductionSignal Transductionmedicine.drug
researchProduct

Short term treatment by fenofibrate enhances oxidative activities towards longchain fatty acids in the liver of lean zucker rats

1990

Lean Zucker rats were dosed orally for 1 week with fenofibrate (100 mg/kg/day). Liver weights of treated rats, expressed as per cent of body weight, were increased, while protein, DNA and triacylglycerol contents were not changed to any great extent per gram of liver, but increased when expressed per whole liver. Compared with the control animals, activities of fatty acid oxidase, of the peroxisomal fatty acid-oxidizing system and of catalase were markedly enhanced by fenofibrate, both per gram of liver and per total liver, while urate oxidase activity was slightly depressed when expressed per gram of liver. The activity of cytochrome c oxidase used as a mitochondrial marker was only higher…

medicine.medical_specialtyTime FactorsMitochondria LiverBiologyBiochemistryPalmitic acidchemistry.chemical_compoundFenofibrateInternal medicinemedicineAnimalsCarnitineBeta oxidationFatty acid synthesisPharmacologychemistry.chemical_classificationFenofibrateFatty AcidsFatty acidOrgan SizePeroxisomeRatsRats ZuckerEndocrinologyMalonyl-CoALiverchemistryOxidation-Reductionmedicine.drugBiochemical Pharmacology
researchProduct

Sox17 regulates liver lipid metabolism and adaptation to fasting.

2014

Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum is a biomarker of PPARalpha activation. Here we set up a screen to identify new regulators of adaptation to fasting using the serum Vanin-1 as a marker of PPARalpha activation. Mutagenized mice were screened for low serum Vanin-1 expression. Functional interactions with PPARalpha were investigated by combining transcriptomic, biochemical and metabolic approaches. We characterized a new mutant mouse in which hepatic and serum expression of Vanin-1 is …

medicine.medical_specialtyTransgeneMutantPeroxisome proliferator-activated receptorlcsh:MedicineMice TransgenicGastroenterology and HepatologyBiologyGPI-Linked ProteinsAmidohydrolasesMiceInternal medicineHMGB ProteinsMolecular Cell BiologymedicineMedicine and Health SciencesSOXF Transcription FactorsAnimalsPPAR alphalcsh:ScienceBeta oxidationchemistry.chemical_classificationMultidisciplinaryFatty liverlcsh:RBiology and Life SciencesLipid metabolismSOX9 Transcription FactorCell BiologyFastingmedicine.diseaseLipid MetabolismAdaptation Physiological3. Good healthEndocrinologychemistryPantetheinaseLiverlipids (amino acids peptides and proteins)lcsh:QTranscriptomeDrug metabolismResearch ArticlePLoS ONE
researchProduct

The role of fibrate treatment in dyslipidemia: an overview.

2012

Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributin…

medicine.medical_specialtymedicine.drug_classPeroxisome proliferator-activated receptorAdipokineFibratechemistry.chemical_compoundInternal medicineDrug DiscoverymedicineAnimalsHumansTriglyceridesDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationTriglycerideCholesterolbusiness.industryFibric Acidsnutritional and metabolic diseasesLipid metabolismCholesterol LDLmedicine.diseaseFibrates dyslipidemia cardiovascular risk diabetes.EndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent pharmaceutical design
researchProduct